Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus PRAMINE.
Head-to-head clinical analysis: AVENTYL HYDROCHLORIDE versus PRAMINE.
AVENTYL HYDROCHLORIDE vs PRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline hydrochloride, the active ingredient in Aventyl Hydrochloride, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has antihistaminic, anticholinergic, and sedative properties.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentration in the synaptic cleft.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum dose 150 mg/day.
Imipramine (PRAMINE) 75-150 mg orally once daily at bedtime, titrated from 25-50 mg, max 300 mg/day.
None Documented
None Documented
Clinical Note
moderateImipramine + Torasemide
"The risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide."
Clinical Note
moderateClomipramine + Torasemide
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide."
Clinical Note
moderateImipramine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid."
Clinical Note
moderateClomipramine + Etacrynic acid
Terminal elimination half-life is approximately 19–24 hours; may be prolonged in elderly and patients with hepatic impairment.
10-12 hours (terminal elimination half-life; may be prolonged in elderly and hepatic impairment)
Primarily renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal excretion accounts for ~30%.
Renal: 70% (as metabolites); Fecal: 30% (as metabolites and unchanged drug)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid."